The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
|Videos|May 16, 2022
Dr. Rafael Sanchez-Salas on the ideal patient for focal therapy for prostate cancer
Author(s)Urology Times staff
“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
Advertisement
In this interview, Rafael Sanchez-Salas, MD, also discusses potential complications of focal therapy. Sanchez-Salas is an associate professor of urology in the department of surgery at McGill University in Montreal, Quebec.
Advertisement
Related to this article
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Advertisement
Advertisement
Trending on Urology Times
1
Comparing PSMA-PET agents: What urologists should know
2
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
3
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
4
Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC
5